MedTrace Logo

Effect of Subarachnoid Hyperbaric Bupivacaine in Obese Pregnant Patients Undergoing Cesarean Section

NCT06060015 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2023-09-29

No results posted yet for this study

Summary

Evaluates the effect of hyperbaric subarachnoid bupivacaine at doses of 5 mg vs 10 mg on mean arterial pressure in obese pregnant patients undergoing cesarean section

Conditions

  • Anesthesia
  • Obstetric Anesthesia Problems

Interventions

DRUG

5mg bupivacaine

Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg

DRUG

10mg bupivacaine

Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10 mg

Sponsors & Collaborators

  • Hospital Civil de Guadalajara

    lead OTHER

Principal Investigators

  • María de los Angeles Campechano Ascencio, MSc · Hospital Civil de Guadalajara

  • Miriam Mendez del Villar, PhD · Universidad de Guadalajara Centro Universitario de Tonalá

  • Leonel Garcia Benavides, PhD · Universidad de Guadalajara Centro Universitario de Tonalá

  • Jorge Bravo Rubio, MSc · Hospital Civil de Guadalajara

  • Edy David Rubio Arellano, MSc · Universidad de Guadalajara Centro Universitario Ciencias de la Salud

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06060015 on ClinicalTrials.gov